PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33763493-11	2021	Immunofluorescence assay validated that anti-TROVE2 antibody could highly predict ADAb development and poor EULAR response (AUC 0.79 and 0.89, respectively).	N,n-dimethyl-4,4'-azodianiline	82-86	Ro60, Y RNA binding protein	Homo sapiens	45-51	
33763493-12	2021	Multivariate regression analysis proved anti-TROVE2 antibody to be an independent predictor for developing ADAb.	N,n-dimethyl-4,4'-azodianiline	107-111	Ro60, Y RNA binding protein	Homo sapiens	45-51	
33763493-13	2021	Immune-related protein microarray and replication analysis identified anti-TROVE2 antibody as a useful biomarker for predicting ADAb development and therapeutic response in adalimumab-treated patients.	N,n-dimethyl-4,4'-azodianiline	128-132	Ro60, Y RNA binding protein	Homo sapiens	75-81